Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus PRANTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus PRANTAL.
DICYCLOMINE HYDROCHLORIDE vs PRANTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Prantal (diphemanil methylsulfate) is a quaternary ammonium anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing gastrointestinal motility, gastric acid secretion, and bronchial secretions. It does not cross the blood-brain barrier.
10-20 mg orally 3-4 times daily
50-100 mg orally 3-4 times daily; maximum 600 mg/day
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life is 4-6 hours; steady-state achieved within 24 hours in patients with normal renal function.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Primarily renal (50-70% unchanged) with minor biliary excretion; fecal elimination accounts for approximately 10-20%.
Category A/B
Category C
Anticholinergic
Anticholinergic